Primary Progressive Multiple Sclerosis
37
4
6
20
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
10.8%
4 terminated out of 37 trials
83.3%
-3.2% vs benchmark
19%
7 trials in Phase 3/4
35%
7 of 20 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 20 completed trials
Clinical Trials (37)
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis
Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS
Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis
Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care
SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis
Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
Metformin Treatment in Progressive Multiple Sclerosis
Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration
A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis
ACTH in Progressive Forms of MS
Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)
Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK Study
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
Gray Matter Demyelination in Primary Progressive MS at 7T